相关实验视频
Updated: Jun 7, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
苏尔福拉抑制了血管认知障碍中的Aβ积累和tau过酸化 (VCI)
1School of Medical Information Engineering, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, Shandong, China.
The Journal of nutritional biochemistry
|November 17, 2024
概括
硫,一个来自十字植物蔬菜的化合物,显示出保护大脑的承诺. 它减少了血管认知障碍 (VCI) 模型中的白质损伤和认知衰退,为痴呆症治疗提供了潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 血管认知障碍 (VCI) 和阿尔茨海默病 (AD) 是导致痴呆的主要原因.
- 大脑血管病变有助于VCI,神经退行和AD病理.
- 硫福拉 (Sfn) 是一种具有已知的抗氧化和抗炎性能的天然化合物.
研究的目的:
- 在VCI的老鼠模型中研究硫甲 (Sfn) 的保护作用.
- 确定Sfn对白质损伤,神经缩和AD关键病理 (Aβ和p-tau) 的影响.
主要方法:
- 通过使用永久双边常见动脉封闭 (2VO) 来诱导VCI的老鼠模型.
- 评估了Sfn给药对认知缺陷,病理变化和分子标记物的影响.
- 研究的关键途径包括HO-1表达,Akt/GSK3β信号传递和粉样蛋白前体蛋白 (APP) 水平.
主要成果:
- 在VCI模型中,Sfn改善了血管认知缺陷,并减少了白质损伤和神经缩.
- Sfn显著降低了粉样β (Aβ) 和酸化 (p-tau) 的积累.
- 保护机制包括HO-1诱导,Akt/GSK3β通路激活和APP表达的调节.
结论:
- 苏尔福拉显示出对VCI和相关病理的显著神经保护作用.
- 斯芬抑制了急性神经元/白质损伤和慢性Aβ/p-tau积累.
- Sfn是治疗VCI和阿尔茨海默病的潜在治疗剂.
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165

